September 30, 2019

Protecting the health of shareholders, not patients

Political Dig -  J. Michael Pearson, the CEO of Valeant Pharmaceuticals has enraged the internet after saying in a recent interview with MSNBC that “his company’s responsibility is to its shareholders, not the customers who rely on his drugs to live.”

“My primary responsibility is to Valeant shareholders. We can do anything we want to do. We will continue to make acquisitions, we will continue to move forward,” Pearson said.

He added: “If products are sort of mispriced and there’s an opportunity, we will act appropriately in terms of doing what I assume our shareholders would like us to do.”

Already this year, according to several media outlets, Valeant has increased the price of 56 of the drugs in its portfolio an average of 66 percent, highlighted by their recent acquisition, Zegerid, which they promptly raised 550 percent. Not only does this have the unfortunate side effect of placing the price of life-saving drugs out of reach for even moderately-insured people, but it has now begun to call into question the sustainability of this rapidly-spreading business model.

No comments: